AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

The Real-World GLP-1 Care Pathway for Obesity Treatment: Persistence, Dose Attainment, Monitoring, and Weight Loss Response

By Yang H, Kim C, Huang C et al.

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) produce substantial weight loss in randomized trials. However, real-world effectiveness depends on successful progression through a series of post-initiation care steps, including treatment persistence, dose attainment, weight monitoring, and assessment of treatment response, yet the extent of attrition across this care pathway is unknown. Hypothesis: We hypothesized that most patients initiating GLP-1-based obesity therapy would not persist on treatment long enough to achieve clinically meaningful weight loss, and that observed weight loss outcomes would be strongly influenced by progression through the care pathway. Methods: We conducted a retrospective cohort study using the Epic Cosmos dataset (>350 US health systems) among adults with obesity (BMI ≥30 kg/m ² or BMI ≥27 kg/m ² with at least one obesity-related comorbidity) without diabetes who initiated injectable semaglutide or tirzepatide between January 1 and December 31, 2024. Patients were followed for up to 12 months. Treatment patterns—including persistence, switching, add-on therapy, and reinitiation—were characterized at 3, 6, and 12 months. Weight outcomes were categorized as response (≥5% total body weight loss [TBWL] from baseline), non-response (<5% TBWL), or no weight recorded, with ≥10% TBWL evaluated as a sensitivity threshold. All outcomes were described according to treatment persistence status. Results: The cohort included 743,153 adults initiating injectable semaglutide (n=446,336) or tirzepatide (n=296,817) for obesity. Persistence declined rapidly over time, with 70.1%, 53.4%, and 32.3% of patients remaining on therapy at 3, 6, and 12 months, respectively. By 12 months, 29.9% of semaglutide initiators and 35.9% of tirzepatide initiators remained on therapy; 15.8% and 30.0% of all initiators, respectively, were both persistent and had reached maintenance dose. Among all semaglutide initiators, 25.6% achieved ≥5% TBWL and 16.4% achieved ≥10% TBWL in total; corresponding rates were 30.4% and 22.5% among tirzepatide initiators. Among patients persistent for ≥12 months, response rates at 12 months were higher: 35.4% and 24.9% of semaglutide users achieved ≥5% and ≥10% TBWL, respectively, compared with 42.8% and 35.5% among tirzepatide users. Notably, the absence of a recorded weight at 12 months was itself a substantive outcome, affecting approximately 50% of patients regardless of persistence status. Conclusions: In this nationwide cohort, most patients initiating GLP-1-based obesity therapy did not remain visible in care long enough for treatment benefit to be observed. The real-world promise of these medications is filtered through a fragile and selective care pathway; improving post-initiation care infrastructure may be as important as pharmacologic potency in achieving population-level effectiveness.

doi.org/10.1161/circ.154.suppl_1.8935Interventions

AgingResearch.News